Clinical Trials Logo

Hereditary Angioedema clinical trials

View clinical trials related to Hereditary Angioedema.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04091113 Terminated - Clinical trials for Hereditary Angioedema

Hereditary Angioedema Kininogen Assay

HAEKA
Start date: September 1, 2019
Phase:
Study type: Observational

A multicenter epidemiological observational study aiming to explore the cleaved high-molecular weight kininogen (cHMWK) including identification and characterization of other metabolite/biomarkers in HAE type 1/2 patients

NCT ID: NCT02854397 Terminated - Healthy Volunteers Clinical Trials

Determination of Specific Biomarkers of Acute Attack of Angioedema Within Pediatric Population

BRADYKID
Start date: February 15, 2016
Phase:
Study type: Observational

In emergency room, this is crucial to diagnose an acute attack of hereditary angioedema (HAE) to quickly provide the efficient treatment. Currently, there is no specific biomarker for acute attack of bradykinin-mediated angioedema to help clinicians for patient care. However, previous works are carried out for that purpose. All the potential candidate biomarkers must be validated in prospective studies to estimate their specificity and sensitivity values, and to understand their potential utility in patient care. The main goal of this clinical trial is to estimate the diagnostic value of VE-cadherin in pediatric population, for the differential diagnosis between HAE crisis and angioedema resulting of mast cell activation crisis (the main differential diagnosis of HAE).

NCT ID: NCT02670720 Terminated - Clinical trials for Hereditary Angioedema

Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema

OPuS-4
Start date: December 2015
Phase: Phase 3
Study type: Interventional

This is an open-label study designed to evaluate the long-term safety of prophylactic avoralstat (500 mg three times daily) when given to approximately 150 patients with hereditary angioedema (HAE) for a duration of up to 72 weeks. The study will also evaluate the long-term efficacy and impact on quality of life of avoralstat prophylactic treatment.